Grafa News and Videos — Page 613

Silence Therapeutics (NASDAQ:SLN) reported positive follow-up and quality-of-life clinical data for its experimental blood cancer treatment, divesiran, demonstrating a sustained reduction in the medical procedures required to manage the rare disease.

Driven Brands Holdings (NASDAQ:DRVN) reported a rise in profit and revenue for the first quarter of fiscal 2026, supported by robust performance in its quick-lube business even as the company navigates elevated corporate expenses stemming from its recent financial restatements.

Nurix Therapeutics (NASDAQ:NRIX) released updated Phase 1a/b clinical data for its experimental leukemia drug, bexobrutideg, demonstrating sustained efficacy and high response rates across multiple lines of therapy for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The Lovesac Company (NASDAQ:LOVE) reported a net loss for its fiscal 2027 first quarter, reflecting the persistent operational difficulties home furnishings retailers face as sticky inflation and elevated mortgage rates suppress discretionary consumer spending.

Takeda Pharmaceutical (NYSE:TAK) reported positive topline results from a head-to-head Phase 3 clinical trial for its experimental plaque psoriasis drug, zasocitinib, positioning the oral pill to challenge established autoimmune blockbusters.

Merck Animal Health, a subsidiary of pharmaceutical giant Merck & Co (NYSE:MRK), signed a definitive agreement to acquire TARGAN, a privately held agtech developer specializing in high-speed automated biodevices for commercial hatcheries.

Parsons (NYSE:PSN) has secured a $22 million contract amendment from the Los Angeles County Metropolitan Transportation Authority to expand infrastructure and transit enhancements along the Interstate 605 corridor.

The board of directors of Target (NYSE:TGT) declared a quarterly cash dividend of $1.16 per common share, representing a 1.8% increase over its previous distribution baseline.

Dana Incorporated (NYSE:DAN) has reached a definitive agreement to combine with Eaton's (NYSE:ETN) Mobility business, a blockbuster industrial carve-out that values the division at $5.1 billion and establishes a premier global vehicle powertrain supplier.

Copley Acquisition (NYSE:COPL) and Ignite Proteomics entered into a definitive business combination agreement that will take the biotech firm public at a pro forma enterprise value of $150 million.